TY  - CONF
AU  - Grahovac, J.
AU  - Živić, K.
AU  - Pavlović, M.
AU  - Ostojić, M.
AU  - Đurić, A.
AU  - Srdić Rajić, T.
AU  - Pavić, Aleksandar
AU  - Galun, D.
PY  - 2023
UR  - https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13471
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1912
AB  - Introduction: Pancreatic ductal adenocarcinoma (PDAC) has dismal
prognosis, as there are no screening tests available, most
often is diagnosed in the metastatic phase of the disease
and is refractory to conventional, targeted and
immunotherapy. We have examined the expression and
role of the novel tumor suppressor nischarin (NISCH) in
PDAC and the effects of treatment with the agonist
rilmenidine (approved for treatment of hypertension) in
order to determine the potential of nischarin agonists for
repurposing in this deadly disease.
PB  - Wiley
C3  - Molecular oncology
T1  - Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma
EP  - 348
IS  - Supplement 1
SP  - 347
VL  - 17
DO  - doi.org/10.1002/1878-0261.13471
ER  - 

@conference{
author = "Grahovac, J. and Živić, K. and Pavlović, M. and Ostojić, M. and Đurić, A. and Srdić Rajić, T. and Pavić, Aleksandar and Galun, D.",
year = "2023",
abstract = "Introduction: Pancreatic ductal adenocarcinoma (PDAC) has dismal
prognosis, as there are no screening tests available, most
often is diagnosed in the metastatic phase of the disease
and is refractory to conventional, targeted and
immunotherapy. We have examined the expression and
role of the novel tumor suppressor nischarin (NISCH) in
PDAC and the effects of treatment with the agonist
rilmenidine (approved for treatment of hypertension) in
order to determine the potential of nischarin agonists for
repurposing in this deadly disease.",
publisher = "Wiley",
journal = "Molecular oncology",
title = "Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma",
pages = "348-347",
number = "Supplement 1",
volume = "17",
doi = "doi.org/10.1002/1878-0261.13471"
}

Grahovac, J., Živić, K., Pavlović, M., Ostojić, M., Đurić, A., Srdić Rajić, T., Pavić, A.,& Galun, D.. (2023). Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma. in Molecular oncology
Wiley., 17(Supplement 1), 347-348.
https://doi.org/doi.org/10.1002/1878-0261.13471

Grahovac J, Živić K, Pavlović M, Ostojić M, Đurić A, Srdić Rajić T, Pavić A, Galun D. Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma. in Molecular oncology. 2023;17(Supplement 1):347-348.
doi:doi.org/10.1002/1878-0261.13471 .

Grahovac, J., Živić, K., Pavlović, M., Ostojić, M., Đurić, A., Srdić Rajić, T., Pavić, Aleksandar, Galun, D., "Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma" in Molecular oncology, 17, no. Supplement 1 (2023):347-348,
https://doi.org/doi.org/10.1002/1878-0261.13471 . .